Erschienen in:
29.08.2020 | BRIEF COMMUNICATION
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center
verfasst von:
Eleonora Matteo, Valentina Favoni, Alessia Pascazio, Umberto Pensato, Matteo Benini, Gian Maria Asioli, Elena Merli, Calogero Calabrò, Pietro Cortelli, Giulia Pierangeli, Sabina Cevoli
Erschienen in:
Neurological Sciences
|
Sonderheft 2/2020
Einloggen, um Zugang zu erhalten
Excerpt
Migraine is one of the most prevalent and disabling conditions worldwide. Treatment of migraine can involve both acute and preventive interventions. Patients with frequent headache may require both approaches. Acute treatment is aimed at aborting the headache attack, whereas preventive treatment is geared toward reducing the frequency and severity of attacks. Monoclonal antibodies against CGRP (mAbs) are a novel therapeutic preventive option for patients with migraine [
1]. Among mAbs, erenumab selectively targets the CGRP receptor. Randomized controlled trials have proven efficacy and safety of erenumab as preventive treatment for both episodic and chronic migraine (CM); however, real-life studies are still needed to confirm these results in everyday clinical practice. …
